Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.
Location: United States, Massachusetts, Boston
Employees: 51-200
Total raised: $1M
Founded date: 2001
Investors 5
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
| - | DBL Partne... | dbl.vc |
| 08.05.2021 | DBL Partne... | dblpartner... |
| - | Lightstone... | lightstone... |
| - | TPG | tpg.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.05.2010 | - | $1M | - |
Mentions in press and media 9
| Date | Title | Description |
| 09.03.2021 | Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 9, 2021-- Five Prime Therapeutics, Inc. (NASDAQ: FPRX) announced today that it has canceled its fourth quarter and full year 2020 earnings conference call, which was previously scheduled for... |
| 19.02.2020 | Drug at center of $1.7B BMS, Five Prime partnership fails in Phase II pancreatic cancer study | The partnership between the two companies had been announced in October 2015 and was focused on the development of cabiralizumab, then known as FPA008. BMS would have paid Five Prime up to $1.74 billion, including an upfront payment of $350... |
| 29.07.2013 | Five Prime Therapeutics pitches $60M IPO after string of pharma collaborations | Five Prime Therapeutics wants to follow more than two dozen other drug developers this year onto the public market. The South San Francisco-based biotech, a developer of protein drugs, has filed paperwork to complete an initial public offer... |
| 18.04.2012 | GSK, FivePrime partner to discover new asthma and COPD treatments | Over the next four years, privately held FivePrime stands to gain up to $30 million from the new deal in the form of up-front payments, GSK purchase of FivePrime equity, research funding and option payments related to the program. FivePrime... |
| 25.05.2010 | Five Prime Therapeutics Receives $1M to Develop Candidate for Treatment of Multiple Sclerosis | Five Prime Therapeutics, Inc., a San Francisco, CA-based developer of innovative protein and antibody therapeutics, has received a $1m funding from Fast Forward, LLC, a subsidiary of the National Multiple Sclerosis Society. The funding will... |
| - | GSK, FivePrime partner to discover new asthma and COPD treatments | GlaxoSmithKline (NYSE:GSK) is partnering with California biotechnology company Five Prime Therapeutics to discover new treatments for respiratory disorders. It’s the second drug discovery alliance in two years that involves the companies. I... |
| - | Five Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 2, 2021-- Five Prime Therapeutics, Inc. (NASDAQ: FPRX), will report its fourth quarter and full year 2020 operational and financial results on Wednesday, March 10, 2021 after the U.S. financ... |
| - | Drug at center of $1.7B BMS, Five Prime partnership fails in Phase II pancreatic cancer study | A clinical trial that was a big part of a more than $1 billion partnership between a large drugmaker and a small-cap biotech company has flopped. South San Francisco, California-based Five Prime Therapeutics said Tuesday that it had receive... |
| - | Five Prime Therapeutics to Participate in the Cowen 41st Annual Health Care Conference | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 26, 2021-- Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Med... |